NanoMed Pharmaceuticals

NanoMed Pharmaceuticals was a specialty biotechnology company focused on the development of nanoparticle-based drug delivery systems to improve the therapeutic index of existing and novel drugs. The company's core technology, the Nanotaxi platform, utilized biodegradable polymers to encapsulate therapeutic agents, enabling targeted delivery and controlled release. Its primary research efforts were directed toward enhancing treatments for HIV and various forms of cancer by reducing systemic toxicity and improving bioavailability. Although the company made significant strides in pre-clinical development and established academic ties with Rutgers University, it is no longer active in the commercial biotech sector.